Thermo Fisher AI Stock Analysis
Want to see TMO full AI Analyst Report?
Thermo Fisher (TMO) AI Stock Analysis
Thermo Fisher
(NYSE:TMO)
The score is driven primarily by strong financial quality and cash generation, supported by a clearly bullish technical trend and a very positive, guidance-raising earnings call. These strengths are partially offset by a high valuation (P/E 36.915) and meaningful leverage, alongside pockets of uneven demand (e.g., flat academic/government and muted reagent environment).
Thermo Fisher Key Performance Indicators (KPIs)
Operating Income by SegmentShows the profitability of different business segments, highlighting which areas are driving earnings and where there may be opportunities or challenges.
Life Sciences Solutions has re-based well below its pandemic-era peaks and is only marginally recovering, so it no longer singularly drives Thermo Fisher’s profitability; instead, Laboratory Products and Analytical Instruments have materially grown their operating-income share—Analytical Instruments in particular shows sharp margin uplift—supporting the company’s raised guidance and margin expansion. That momentum is reinforced by recent acquisitions and product launches, but the microbiology divestiture, reduced FX tailwind and elevated leverage temper near-term EPS upside.
Thermo Fisher (TMO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $256.15B
- Dividend Yield
- 0.27%
- Average Volume (3M)
- 2.16M
- Price to Earnings (P/E)
- 36.4
- Beta (1Y)
- 0.72
- Revenue Growth
- 8.27%
- EPS Growth
- 9.59%
- Country
- US
- Employees
- 125,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Thermo Fisher Business Overview & Revenue Model
Company Description
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio o...
How the Company Makes Money
Thermo Fisher makes money by selling a mix of recurring consumables/services and higher-ticket capital equipment, primarily to pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laborator...
Thermo Fisher Earnings Call Summary
The call was strongly positive. Thermo Fisher delivered broad-based revenue, profit, margin, cash flow, and organic growth improvements; exceeded prior guidance; raised full-year revenue, EPS, and free cash flow guidance; and reported continued momentum in pharma, biotech, analytical instruments, AI, clinical research, and bioproduction. The main challenges were flat academic and government revenue, a decline in reported Specialty Diagnostics revenue, muted reagent demand, unfavorable mix, and some Pharma Services timing between the third and fourth quarters.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, guidance is revenue of $47.7 billion-$48.2 billion, representing 7%-8% reported revenue growth over 2025 and full-year organic revenue growth of 4%; adjusted earnings per share is $25.13-$25.43 per share, representing 10%-11% growth; fourth-quarter organic revenue growth is expected to be 4%, with a year over year revenue tailwind from foreign exchange of approximately $200 million for the year; guidance assumes 80 basis points of adjusted operating income margin expansion, approximately $650 million of net interest expense, an adjusted income tax rate of 11.5%, between $1.9 billion and $2 billion of net capital expenditures, free cash flow between $7 billion and $7.5 billion, $4 billion of share buybacks, approximately $700 million of capital returned through dividends, and a full-year average diluted share count between 371 million and 372 million shares.
Thermo Fisher Financial Statement Overview
Summary
Fundamentals are solid, led by strong profitability (TTM gross margin ~41%, operating margin ~18.6%, net margin ~15.1%) and strong cash generation (TTM OCF $9.32B; FCF $7.60B; ~81% FCF-to-net-income). Offsets include post-2021 growth normalization (dip in 2023, modest 2024–2025 growth) and meaningful leverage (debt-to-equity ~0.81; debt $41.4B), with only moderate cash flow coverage (~0.60).
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
81Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.35B | 44.56B | 42.88B | 42.86B | 44.91B | 39.21B |
| Gross Profit | 19.62B | 18.24B | 17.73B | 17.19B | 19.01B | 19.63B |
| EBITDA | 11.24B | 11.47B | 11.80B | 11.20B | 11.94B | 11.97B |
| Net Income | 7.08B | 6.74B | 6.33B | 6.00B | 6.95B | 7.72B |
Balance Sheet | ||||||
| Total Assets | 114.23B | 110.34B | 97.32B | 98.73B | 97.15B | 95.12B |
| Cash, Cash Equivalents and Short-Term Investments | 6.06B | 10.11B | 5.58B | 8.08B | 8.52B | 4.48B |
| Total Debt | 41.37B | 39.38B | 32.77B | 36.42B | 36.07B | 36.34B |
| Total Liabilities | 59.47B | 56.81B | 47.65B | 51.88B | 53.01B | 54.15B |
| Stockholders Equity | 54.76B | 53.41B | 49.58B | 46.73B | 43.98B | 40.79B |
Cash Flow | ||||||
| Free Cash Flow | 7.60B | 6.29B | 7.27B | 6.93B | 6.91B | 6.79B |
| Operating Cash Flow | 9.32B | 7.82B | 8.67B | 8.41B | 9.15B | 9.31B |
| Investing Cash Flow | -7.98B | -4.05B | -5.84B | -5.14B | -2.16B | -21.93B |
| Financing Cash Flow | 985.00M | 1.80B | -6.79B | -3.62B | -2.81B | 6.58B |
Thermo Fisher Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TMO, the sentiment is Neutral. The current price of 691.33 is below the 20-day moving average (MA) of 696.37, above the 50-day MA of 672.13, and above the 200-day MA of 555.33, indicating a neutral trend. The MACD of 9.19 indicates Positive momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 53.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TMO.
Thermo Fisher Risk Analysis
Thermo Fisher disclosed 26 risk factors in its most recent earnings report. Thermo Fisher reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
2 New RisksThermo Fisher Peers Comparison
Overall Rating
IDXX82Outperform
TMO76.9Outperform
A75Outperform
MTD75Outperform
DHR73Outperform
WAT59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | $55.20B | 47.37 | 71.18% | ― | 11.87% | 17.33% | |
| 77Outperform | $256.15B | 36.40 | 13.31% | 0.27% | 8.27% | 9.59% | |
| 75Outperform | $48.75B | 34.01 | 20.47% | 0.59% | 8.60% | 19.07% | |
| 75Outperform | $34.36B | 37.38 | 9999.00% | ― | 6.51% | 15.03% | |
| 73Outperform | $161.75B | 37.78 | 8.18% | 0.66% | 5.52% | 25.53% | |
| 59Neutral | $44.56B | 192.94 | 0.81% | ― | 80.68% | -78.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific | 691.33 | 117.32 | 20.44% | |
| A | Agilent Technologies | 172.92 | 30.15 | 21.12% | |
| DHR | Danaher Corporation | 229.91 | 6.05 | 2.70% | |
| IDXX | Idexx Laboratories | 700.65 | 30.44 | 4.54% | |
| MTD | Mettler-toledo International | 1727.26 | 330.81 | 23.69% | |
| WAT | Waters Corp | 453.42 | 76.79 | 20.39% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026
